Orbimed Advisors LLC Arcus Biosciences, Inc. Transaction History

Orbimed Advisors LLC

  • $4.24 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$13.43 - $19.63 $1.57 Million - $2.3 Million
117,000 New
117,000 $2.23 Million
Q3 2022

Nov 14, 2022
BUY
$23.23 - $30.07 $7.04 Million - $9.11 Million
303,000 New
303,000 $7.93 Million
Q3 2020

Nov 16, 2020
SELL
$17.14 - $25.47 $3.78 Million - $5.61 Million
-220,350 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$13.97 - $36.56 $3.08 Million - $8.06 Million
220,350 New
220,350 $5.45 Million

Others Institutions Holding RCUS

# of Institutions
196
Shares Held
51.6M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $906M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email